13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Harmony GO29833

    Acronym: 

    Harmony GO29833

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Phase Ib/II Study Evaluating the Safety and Efficacy of MPDL3280A in combination with either Obinutuzumab plus bendamustine or Obinutuzumab plus chop in patients with follicular lymphoma or diffuse large B-cell lymphoma

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase I, Phase II Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase Phase I, Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with polatuzumab vedotin and ventoclax in patietns with relpased or refractory follicular lymphoma and Rituximab in combination with Polatuzumab Vedotin and Ventoclax in patietns with relapsed or refractory diffuse large B-cell lymphoma

    Lay Summary

    A Phase Ib/II Study Evaluating the Safety and Efficacy of MPDL3280A in combination with either Obinutuzumab plus bendamustine or Obinutuzumab plus chop in patients with follicular lymphoma or diffuse large B-cell lymphoma

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 U Hahn Recruiting